Evidence map›Paper›PMID 29902182›Full record

ArticlePloS one2018

Triticum vulgare extract exerts an anti-inflammatory action in two in vitro models of inflammation in microglial cells.

Luca Sanguigno, Antonella Casamassa, Niccola Funel, Massimiliano Minale, Rodolfo Riccio, Salvatore Riccio, Francesca Boscia, Paola Brancaccio, Luca Emanuele Pollina, Serenella Anzilotti and 2 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Pharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Evaluation of Biological Effect ofAdvances in pharmacological and pharmaceutical sciences · 2026
    Article
  4. Article
  5. Article
  6. Efficacy of a Novel RigenaseMedicina (Kaunas, Lithuania) · 2023
    Observational
  7. Journal of clinical medicine · 2023
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. AClinical, cosmetic and investigational dermatology · 2020
    Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Luca SanguignoDepartment of Molecular Medicine and Medical Biotechnology, School of Medicine, Federico II University of Naples, Naples, Italy.
Antonella CasamassaDivision of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, Naples, Italy.
Niccola FunelDepartment of Translational Research and The New Technologies in Medicine and Surgery, University of Pisa, Italy.
Massimiliano MinaleFarmaceutici Damor S.p.A, Naples, Italy.
Rodolfo RiccioFarmaceutici Damor S.p.A, Naples, Italy.
Salvatore RiccioFarmaceutici Damor S.p.A, Naples, Italy.
Francesca BosciaDivision of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, Naples, Italy.
Paola BrancaccioDivision of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, Naples, Italy.
Luca Emanuele PollinaSecond Division of Surgical Pathology, Hospital of Pisa, Italy.
Serenella AnzilottiIRCSS SDN, Naples, Italy.
Gianfranco Di RenzoDivision of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, Naples, Italy.
Ornella CuomoDivision of Pharmacology, Department of Neuroscience, Reproductive and Dentistry Sciences, School of Medicine, Federico II University of Naples, Naples, Italy.ORCID 0000-0002-6459-2530
University of Naples Federico II · ITFarmaceutici Damor (Italy) · ITAzienda Ospedaliera Universitaria Pisana · ITSDN Istituto di Ricerca Diagnostica e Nucleare · ITUniversity of Pisa · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triticum vulgare has been extensively used in traditional medicine thanks to its properties of accelerating tissue repair. The specific extract of Triticum vulgare manufactured by Farmaceutici Damor (TVE-DAMOR) is already present in some pharmaceutical formulations used in the treatment of decubitus ulcers, skin lesions and burns. It has been recently suggested that this Triticum vulgare extract may possess potential anti-inflammatory properties. In the light of these premises the aim of the present paper was to verify the anti-inflammatory role of TVE, using the LPS-stimulated microglia model of inflammation. In particular the effect of different concentrations of TVE on the release of several mediators of inflammation such as nitric oxide, IL-6, PGE2 and TNF alpha was evaluated. More important, the anti-inflammatory effect of TVE was confirmed also in primary rat microglia cultures. The results of the present study show that TVE exerts anti-inflammatory properties since it reduces the release of all the evaluated markers of inflammation, such as NO, IL6, TNF alpha and PGE2 in LPS-activated BV2 microglial cells. Intriguingly, TVE reduced microglia activation and NO release also in primary microglia. Indeed, to verify the pathway of modulation of the inflammatory markers reported above, we found that TVE restores the cytoplasmic expression of p65 protein, kwown as specific marker associated with activation of inflammatory response. The evidence for an inhibitory activity on inflammation of this specific extract of Triticum vulgare may open the way to the possibility of a therapeutical use of the Triticum vulgare extract as an anti-inflammatory compound in certain pathological states such as burns, decubitus ulcers, folliculitis and inflammation of peripheral nerve.

Indexed as

AnimalsDinoprostoneeIF-2 KinaseGene Expression RegulationHumansInflammationInterleukin-6LipopolysaccharidesMiceMicrogliaNitric OxidePlant ExtractsRatsTriticumTumor Necrosis Factor-alphaDinoprostoneeIF-2 KinaseInterleukin-6LipopolysaccharidesNitric OxidePlant ExtractsTumor Necrosis Factor-alpha

Identifiers

PMID29902182
PMCPMC6002026
OpenAlexW2808160149

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.